• By ICR Secretariat
  • Posted Thursday, June 30, 2022

Novartis lung cancer drug Tabrecta gets approval

https://www.pharmatimes.com/news/novartis_lung_cancer_drug_tabrecta_gets_approval_1450335

Novartis has announced that the European Commission (EC) has approved Tabrecta – also known as capmatinib – as a monotherapy for the treatment of adults with advanced non-small cell lung cancer (NSCLC).